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Melatonin, a product of the pineal gland, is released from the gut mucosa in response to food ingestion. Speciﬁc receptors for
melatonin have been detected in many gastrointestinal tissues including the pancreas. Melatonin as well as its precursor, L-
tryptophan, attenuates the severity of acute pancreatitis and protects the pancreatic tissue from the damage caused by acute
inﬂammation. The beneﬁcial eﬀect of melatonin on acute pancreatitis, which has been reported in many experimental studies and
supported by clinical observations, is related to: (1) enhancement of antioxidant defense of the pancreatic tissue, through direct
scavenging of toxic radical oxygen (ROS) and nitrogen (RNS) species, (2) preservation of the activity of antioxidant enzymes; such
as superoxide dismutase (SOD), catalase (CAT), or glutathione peroxidase (GPx), (3) the decline of pro-inﬂammatory cytokine
tumor necrosis α (TNFα) production, accompanied by stimulation of an anti-inﬂammatory IL-10, (4) improvement of pancreatic
blood ﬂow and decrease of neutrophil inﬁltration, (5) reduction of apoptosis and necrosis in the inﬂamed pancreatic tissue,
(6) increased production of chaperon protein (HSP60), and (7) promotion of regenerative process in the pancreas. Conclusion.
Endogenous melatonin produced from L-tryptophan could be one of the native mechanisms protecting the pancreas from acute
damage and accelerating regeneration of this gland. The beneﬁcial eﬀects of melatonin shown in experimental studies suggest that
melatonin ought to be employed in the clinical trials as a supportive therapy in acute pancreatitis and could be used in people at
high risk for acute pancreatitis to prevent the development of pancreatic inﬂammation.
1.M elat o nininPinealGlandand
intheGastrointestinalTract
More than 50 years ago, Aaron Lerner, a dermatologist
from Yale University, discovered melatonin (5-methoxy-N-
acetyltryptamine) in the pineal gland. The name of this
indoleamine comes from its eﬀect on melanocytes [1]. Mela-
tonin is produced from amino acid precursor; L-tryptophan
anditsproductionandreleasefromthepinealglandundergo
rhythmic diurnal/nocturnal ﬂuctuations, with the peak at
night and lowest level on the light phase [2–4].
Although melatonin has been recognized as the pineal
hormone, subsequent studies have shown that melatonin
could be synthesized in many tissues and that the gas-
trointestinal tract appears to be the main source of
this substance [5–7]. Two main enzymes involved in
the control of melatonin production, arylalkylamino-N-
acetyl-serotonin-transferase (AA-NAT) and hydroxyindolo-O-
methyl-transferase (HIOMT), have been detected in the gas-
trointestinal system [8, 9]. In addition, the estimated level
of melatonin in the gastrointestinal tract was 400 times
higher than that in the pineal gland [10]. In the gut, this
indoleamineisproducedmainlyintheenteroendocrine(EE)
cells;however,highconcentrationofmelatoninhasalsobeen
found in the bile [11–14]. Melatonin is released from the
gastrointestinal mucosa in response to ingested food and this
process is independent from the light/dark cycle and from
the pineal gland [7, 15].
Previous studies have suggested that melatonin could
be produced in the pancreas; the mRNA signal for AA-
NAT, an enzyme involved in the synthesis of melatonin
from L-tryptophan, has been detected in the isolated rat2 International Journal of Inﬂammation
pancreatic acinar cells [16], and gene expression for HIOMT,
another enzyme controlling the above reaction has been,
discovered in the human pancreas [17]. Recent studies
revealed that melatonin and its receptors are present in the
pancreatic gland [18]. Even though melatonin production
in the pancreas is independent from the pineal gland, the
content of melatonin in the pancreatic tissue undergoes
rhythmic diurnal/nocturnal ﬂuctuations [19].
It is interesting to compare diurnal/nocturnal ﬂuctua-
tions of melatonin in the pancreas, pineal gland, and in the
plasma. Nocturnal concentration of melatonin in the pineal
gland was about 1600pg/100mg, whereas, in the daytime,
this concentration was reduced to about 150pg/100mg. This
corresponds to the plasma levels of melatonin, which reaches
150pg/mL at night, whereas, throughout the day, it was
much lower (60pg/mL). In the pancreatic tissue, the above-
mentioned diﬀerences between nocturnal concentration of
melatonin and its daily content were less pronounced and
achieved 10 and 5pg/100mg of tissue, respectively [18].
Melatonin membrane receptors have been identiﬁed
in the human endocrine pancreas, and this indoleamine
has been proposed as one of the modulators of insulin
secretion [20]. The abnormal secretion of melatonin was
observed in type 2 diabetes, which may contribute to the
pathogenesis of this disease [21–24]. In spite of the presence
of melatonin in the pancreas and melatonin receptors in
the pancreatic tissue, the role of this substance in the
physiological regulation of pancreatic functions is still not
complete.
Melatonin has also been recognized as a potent pancre-
atic secretagogue. Administration of melatonin or its amino
acid precursor, L-tryptophan, to the animals resulted in
the spectacular enhancement of pancreatic enzyme secretion
accompanied by a signiﬁcant increase of CCK plasma level
[25]. Stimulatory eﬀects of melatonin or L-tryptophan were
much stronger following intraduodenal than intraperitoneal
administration of investigated substances. The results of
experimental studies suggest that melatonin activates cholin-
ergic enteropancreatic reﬂex to increase pancreatic enzyme
secretion [26]. It is very likely that melatonin produced in
the gut lumen in response to food ingestion is implicated in
the physiological regulation of pancreatic exocrine function.
2. Anti-Inﬂammatory Effects of Melatonin
The physiological signiﬁcance of melatonin was the subject
of several studies. Because of its rhythmic diurnal/nocturnal
ﬂuctuations,melatoninwasbelievedtoregulatethecircadian
rhythms such as hormones release, sleep/wake, and changes
ofbodytemperature[2–4,27].However,themostinteresting
property of melatonin appears to be its anti-inﬂammatory
eﬀect. Melatonin has been recognized as a beneﬁcial sub-
stance, eﬀectively protecting the tissues from inﬂammatory
damage [16, 17, 28–33]. The favorable eﬀect of melatonin,
which has been reported in several studies, depends on two
main mechanisms: (1) antioxidant eﬀects of this indole and
(2) modulation of immune defense induced by melatonin
[34–41].
Melatonin is best known as the scavenger of radical
oxygen (ROS) and nitrogen (RNS) species and activator
of antioxidant enzymes [29, 42–47]. ROS and RNS are
products of mitochondrial metabolism, and, under normal
conditions, they are immediately neutralized by natural
nonenzymatic scavengers and antioxidant enzymes. Mela-
tonin together with reduced glutathione, vitamins C and E,
uric acid, selenium, and creatinine belong to nonenzymatic
scavengers [44, 48, 49]. Antioxidant enzymes such as;
superoxide dismutase (SOD), catalase (CAT), glutathione
peroxydase(GPx),orglutathionereductase(GR)areanother
line of defense against the noxious eﬀect of ROS and RNS
[17,29,43–45].Oxidativestressinacutepancreatitisresulted
in excessive production of ROS and RNS leading to the
impaired ability of tissue to detoxify above intermediates.
ROS and RNS are accumulated in the tissue leading to its
damage [50–52]. The harmful eﬀe c t so fR O Sa n dR N Si n
acute pancreatitis have been conﬁrmed in previous studies
[53, 54]. Melatonin, which is a highly lipophilic substance,
penetrates inside the cells to maintain antioxidant enzymes
activities, to keep the mitochondria from oxidative injury,
and to prevent lipid membranes from peroxidation [55].
Recently melatonin has been shown to trigger signal
transduction pathways leading to the activation of antioxi-
dant enzymes and to the reduction of inﬂammatory medi-
ators in the pancreas [56]. In acute pancreatitis, melatonin
was demonstrated to inhibit nuclear binding of NF-κB,
the transcription factor, which controls the expression of
genes involved in immunity and inﬂammation, production
of prostaglandins, cytokines, cell adhesion molecules, nitric
oxide (NO), and inhibitors of apoptosis [57, 58]. Melatonin
has been demonstrated to reduce gene expression and syn-
thesis of proinﬂammatory cytokine; tumor necrosis factor
α (TNFα), proinﬂammatory interleukins; IL-1β, IL-6, IL-8,
and prostaglandins [56, 59, 60]. In addition, melatonin was
also reported to modulate the processes of apoptosis and
necrosis, to stimulate the production of vascular endothelial
growth factor (VEGF), and to activate the process of
angiogenesis [32, 61, 62]. All of the above eﬀects could be
related to the inhibition of NF-κB by melatonin [56].
Beside the reduction of the above proinﬂammatory
molecular pathway, melatonin enhanced expression of
nuclear factor erythroid 2-related factor (Nrf2), which
activates the signal transduction lane of antioxidant genes
[56]. Since Nrf2 is critically involved in the induction of
antioxidant enzymes such as SOD, CAT, GPx, GST, GR [63]




tors: MT1R, MT2R, MT3R, which have been identiﬁed in
many tissues [64]. Perhaps melatonin exerts its eﬀects also
through intracellular orphan receptors (ROR/RZR), which
have been detected in the nucleus, cytoplasm, and mito-
chondria, but physiological signiﬁcance of these receptors
remains unclear [64, 65]. It is important to emphasize that
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Figure 1: Eﬀect of melatonin on plasma levels of interleukin 10 (IL-10) and tumor necrosis factor α (TNF α) in the rats with acute
pancreatitis (AP). Melatonin or its precursor, L-tryptophan, was given to the rats 30min prior the induction of acute pancreatitis produced
by caerulein overstimulation (5μg/kg-h × 5h). Control-intact rats. Means ± SEM from the separate experiments, each performed on 8–10
rats. Asterisk indicates signiﬁcant increase above the value detected in AP rats alone. Cross indicates signiﬁcant decreases below the value
detected in AP rats alone.
it is highly lipophilic, and on this way melatonin could exert
its biological receptor-independent eﬀects [66].
Production of melatonin is decreased in older individu-
als, and it is believed that the reduction of melatonin level
contributes to the process of aging [67]. Application of this
substance reverses some of degenerative processes related to
old age, and, for this reason, melatonin was suggested to be
the “hormone of youth” [3, 31, 67].
3. Beneﬁcial Effects of Melatonin
onAcutePancreatitis
Experimental studies have shown that application of mela-
tonin signiﬁcantly attenuated the development of acute pan-
creatitis and protected pancreatic tissue against the damage
caused by acute inﬂammation [16, 17, 59–61, 68–75]. In
the rats pretreated with melatonin prior to the induction of
acute pancreatitis, the morphological signs of inﬂammation
such as edema, leukocyte inﬁltration, and cell vacuolization
were dramatically reduced [16, 60, 70–73]. Also other
parameters of acute pancreatitis severity such as blood levels
of amylase or lipase were signiﬁcantly diminished in the
animals pretreated with melatonin, as compared to the rats
with acute pancreatitis alone [16, 17, 59, 68, 70–75]. The
beneﬁcial eﬀect of this indoleamine on acute pancreatitis
was also manifested by the dose-dependent reduction of
proinﬂammatory cytokine TNFα blood level, accompanied
by a marked rise of anti-inﬂammatory interleukin 10 (IL-10)
in the animals subjected to acute pancreatitis and pretreated
with melatonin [16, 69, 70]( Figure 1).
Melatonin is able to diminish the generation of ROS in
the pancreatic tissue, as was demonstrated by the reduced
amount of lipid peroxidation products: MDA + 4HNE in the
pancreas of animals with acute pancreatitis pretreated with
this indoleamine [16, 17, 68, 70–73, 75]. In addition, the
applicationofthementionedprotectivesubstanceresultedin
the signiﬁcant and dose-dependent increase of antioxidant
enzyme (SOD) activity in the pancreatic tissue taken from
the rats with acute pancreatitis [17, 61, 72–74]( Figure 2).
The protective action of melatonin on acute pancre-
atitis was conﬁrmed in several studies, using diﬀerent
models of experimental pancreatitis. Melatonin attenu-
ated acute pancreatitis severity and diminished harmful
eﬀects of acute inﬂammation induced by L-arginine [72],
ischemia/reperfusion, or caerulein overstimulation [16, 59,
61, 68, 70, 74, 76]. Melatonin protected the pancreas against
acute pancreatitis caused by taurocholic acid [60]o rb y
obstruction of pancreatic duct [75]. However, in the model
of necrotizing pancreatitis induced by glycodeoxycholic acid
melatonin appears less eﬀective, because increased serum
amylase level and high mortality rate of experimental
animals was unaﬀected by this indoleamine [77].
It is worth remembering that this substance was also
found to promote the regeneration of pancreatic tissue fol-
lowing the damage caused by acute pancreatitis. Treatment
withmelatoninimprovestherateofDNAsynthesis,aswellas
pancreatic enzyme content in the rats with arginine-induced
pancreatitis [76].
Studies on melatonin revealed that not only mela-
tonin but also its amino acid precursor, L-tryptophan,
is able to attenuate pancreatic tissue damage caused by
acute inﬂammation and to reduce lipid peroxidation in
two models of acute pancreatitis: caerulein-induced and
ischemia/reperfusion pancreatitis [16]. It is likely that the
protective eﬀect of L-tryptophan on acute pancreatitis was4 International Journal of Inﬂammation
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Figure 2: Eﬀect of intraperitoneal (i.p.) application of melatonin or its precursor, L-tryptophan, on concentrations of antioxidative
enzyme superoxide dismutase (SOD) and lipid peroxidation products (MDA + 4-HNE) in the pancreatic tissue taken from rats with acute
pancreatitis (AP). Melatonin or its precursor, L-tryptophan, was applied as explained on Figure 1. Control—intact rats. Means ± SEM from
the separate experiments, each performed on 8–10 rats. Asterisk indicates signiﬁcant increase above the value detected in AP rats alone.










































Figure 3: Plasma level of melatonin in response to intraperitoneal
(i.p.) administration of increasing doses of L-tryptophan. Mela-
tonin plasma level was measured by RIA. Means ± SEM from
the separate experiments, each performed on 8–10 rats. Asterisk
indicates signiﬁcant increase above the control value.
dependent on the conversion of this amino acid into
melatonin, because intraduodenal administration of L-
tryptophan resulted in the signiﬁcant and dose-dependent
increase of plasma melatonin level (Figure 3). These results
lead to the conclusion that endogenous melatonin, which
is produced from L-tryptophan eﬀectively protects the
pancreas from the damage caused by acute inﬂammation
[16].
Application of L-tryptophan at doses of 25 or 50mg/kg
raised the plasma level of melatonin up to 100 or 220pg/mL,
respectively. It is important to underline that pretreatment
of the animals with the above doses of L-tryptophan signif-
icantly attenuates the inﬂammatory process in the pancreas
[16] .S i n c en o r m a lb l o o dl e v e lo fm e l a t o n i nﬂ u c t u a t e sf r o m
50pg/mL (during the light phase) to about 160pg/mL
(at night) [18], it could be assumed that melatonin at
physiological concentrations is able to protect the pancreas
against acute inﬂammatory damage.
This observation indicates that endogenous melatonin
could be one of the physiological protectors of the pancreas.
This notion is supported by the study showing that blockade
of the melatonin receptor aggravated pancreatic damage
caused by caerulein overstimulation. In the rats subjected
to acute pancreatitis and pretreated with melatonin MT1/2
receptor antagonist, luzindole, the histological and biochem-
ical manifestations of pancreatitis were signiﬁcantly higher
than in the group with acute pancreatitis alone [70].
Recent observation from humans with acute pancreatitis
supported and reinforced this hypothesis. It was observed
that melatonin serum level, measured in the ﬁrst 24 hours
after the onset of acute pancreatitis, negatively correlated
with the severity of this illness. In the patients with mild
pancreatitis, serum level of melatonin was markedly higher
than in these with severe form of this disease [78]. This
study presents additional evidence that melatonin could be
one of the natural pancreatic protectors and that high blood
level of this indoleamine has a protective value against acute
pancreatic inﬂammation.
A considerable amount of melatonin is produced in the
gastrointestinalsysteminresponsetofoodingestion,andthis
melatonin is absorbed into the blood stream and represents
the daily pool of this indoleamine, whereas nocturnal level of
melatonin depends on its synthesis in the pineal gland [5, 7,





































































Figure 4: Eﬀect of pinealectomy on pancreatic contents of glutathione peroxidase (GPx) and lipid peroxidation products (MDA + 4-HNE)
inthepancreatictissueofratswithacutepancreatitis.Control—intactrats.Means ±SEMfromtheseparateexperiments,eachperformedon
8–10 rats. Asterisk indicates signiﬁcant increase above the value detected in AP with intact pineal gland. Cross indicates signiﬁcant decrease
below the value detected in AP with intact pineal gland.
thepancreaticprotectionshouldbetakenintoconsideration,
and, to solve this problem, subsequent experiments have
been performed. It has been observed that acute pancreatitis
induced in the dark phase was more severe than during the
day [74]. Because nocturnal melatonin plasma level depends
on the production and release of this substance from the
pineal gland, it is possible that pineal melatonin takes part in
the protection of the pancreas against acute inﬂammation.
A recent study on rats with removed pineal glands give
further evidence for this hypothesis. As we have observed,
acute pancreatitis was much more severe in pinealectomized
animals, than in those with intact pineal glands. This was
manifested by signiﬁcant decrease of an antioxidant enzyme
GPx in the pancreas of pinealectomized rats subjected to
acute pancreatitis, as compared to the animals with intact
pineal glands (Figure 4). Application of melatonin to the
rats deprived of the pineal gland and subjected to acute
pancreatitis signiﬁcantly reduced pancreatic tissue lesions
and attenuated the course of acute inﬂammation [75].
The results of experimental studies and clinical observa-
tions indicate that several mechanisms are involved in the
beneﬁcial eﬀect of melatonin on acute pancreatitis.
3.1. Antioxidative Mechanism. Melatonin as an eﬀective
scavenger of free radicals is able to neutralize above toxic
products directly [16, 17, 68, 70–73]. In addition, this
indoleamine could activate the antioxidant enzymes such
as SOD, CAT, GPx, and GSH and protects them from
inactivation by reactive intermediates. Thus, melatonin
could improve the oxidative status of the pancreatic tissue
indirectly [16, 61, 70, 71, 73–75].
3.2. Modulation of the Immune System. Melatonin is able to
aﬀect the immune system and to strengthen the immune
defense. This substance has been demonstrated to inhibit
neutrophile inﬁltration [16, 70–74], to decrease myeloperox-
idase(MPO)activity[56],andtodiminish theprostaglandin
generation [59] in the inﬂamed pancreas. Recently, mela-
tonin has been shown to reduce mRNA expression of
many proinﬂammatory cytokines such as IL-1 β,I L - 6 ,I L -
8, and TNFα in the pancreatic tissue subjected to acute
inﬂammation [56]. The inhibitory eﬀect of melatonin on
proinﬂammatory cytokine production has been conﬁrmed
by marked reduction of the blood level of TNFα in the
rats with acute pancreatitis pretreated with this indoleamine
[16, 69, 70]. On the contrary; anti-inﬂammatory IL-10 was
increased in these animals [16]. Melatonin enhanced the
expression of nuclear factor erythroid 2-related factor (Nrf2)
and diminished the nuclear binding of NF-κB, and it is likely
that above eﬀects could be involved in the curtailing of acute
pancreatitis by melatonin [56].
3.3. Improvement of Pancreatic Blood Flow. Melatonin has
been demonstrated to increase the blood ﬂow and to remove
the toxic substances from pancreatic tissue [16, 69, 70, 76,
79].
3.4.EﬀectonApoptosis. Melatoninisabletoreduceprocesses
of apoptosis and necrosis in the pancreas [61]. However in
the tumor cells, this substance promotes apoptosis maintain-
ing the viability of normal pancreatic units [80].
3.5. Stimulation of Heat Shock Protein (HSP). HSPs are
known to protect the cell compartment against the damage.
Production of these proteins is augmented in response to
high temperature, oxidative stress, or inﬂammation [81].
Melatonin has been reported to increase mRNA signal
for HSP60 in pancreatic acinar cell line AR42J [82]. It
c o u l db ee x p e c t e dt h a tm e l a t o n i nw o r k st os a v ea c i n a r
cells from acute damage through the stimulation of HSP
production. As was observed, melatonin prevented these
cells from mitochondrial and nuclear damage caused by
acute pancreatitis, reduced the dilatation of endoplasmatic6 International Journal of Inﬂammation
reticulum and Golgi apparatus, and diminish formation of
autophagosomes [72].
3.6. Promotion of Pancreatic Regeneration. It should be
emphasized that administration of melatonin following the
induction of acute pancreatitis not only reduced the severity
of inﬂammation, but also promotes the spontaneous regen-
eration process of the pancreatic tissue. This was manifested
by an increased rate of DNA and protein synthesis and
supported by histological examination [77].
The results of previous experimental studies and clinical
test indicate that melatonin should be employed in clinical
trials as a supportive agent for the treatment of patients with
acute pancreatitis. Melatonin has been used previously as
part of composed therapy in patients with tumors and neu-
rological diseases [82–84]. In patients with cancer melatonin
signiﬁcantly decreased thrombocytopenia, asthenia, neuro-
and cardiotoxicity induced by chemotherapeutic treatment
[82]. It is important to emphasize that the use of this
indoleamineissafe,ithasbeenreportedthatmelatoningiven
at doses of 20mg/day for several weeks in patients with
dyskinesia or with sleep disturbance did not produce any
side eﬀects [84, 85]. It was suggested that melatonin at doses
as high as 50–100mg/day could be applied for treatment
of insomnia and depression [85]. Regarding the beneﬁcial
eﬀects and safety of melatonin use, this substance could also
be introduced as a component of early jejunal feeding in
patients with acute pancreatitis.
4. Conclusion
Endogenous melatonin could be one of the native mech-
anisms protecting the pancreas from acute damage and
accelerating regeneration of this gland. The beneﬁcial eﬀects
of melatonin shown in experimental studies suggest that
melatonin ought to be employed in the clinical trials as a
adjuvant therapy in acute pancreatitis.
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